



September 18, 2014

Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells

Patent Approval Further Strengthens Biocept's IP Position in Personalized Cancer Treatment in East-Asia

SAN DIEGO, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that the Company has been granted a patent in China for its microfluidic channel technology used to capture CTCs. The granted patent is the subject of Chinese Patent No. ZL200780032530.2, entitled, "Detection or Isolation of Target Molecules Using a Microchannel Apparatus."

This patent enhances Biocept's ongoing East-Asia expansion strategy, which aims to increase the adoption of blood-based liquid biopsies to test for biomarkers associated with cancer and help inform patients and their physicians when making treatment decisions.

Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept, said, "The granting of this patent expands Biocept's international IP portfolio and positions the Company well in the Chinese market to be a potential leader in providing innovative technologies for capturing and analyzing circulating tumor cells."

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BR™ test for breast cancer and plans to introduce tests for lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, Biocept can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical (including, without limitation, statements as to the strength of the Company's patents and its technology leadership, the Company's expansion of the geographic area in which it serves patients, and the Company's ability to introduce additional tests for new indications), such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in Biocept's Securities and Exchange Commission (SEC) filings, including without limitation the Company's need to grow its business and operations, the Company's need for capital, and the effects of reimbursement limitations and other health care statutory and regulatory initiatives. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. Readers are advised to review the Company's filings with the SEC, which can be accessed at the SEC's website located at www.sec.gov.

CONTACT: Investor Contact:

The Ruth Group

David Burke

(646) 536-7009

dburke@theruthgroup.com

Media Contact:

The Ruth Group

Calvin Allen

(646) 536-7002

callen@theruthgroup.com

Source: Biocept, Inc.

News Provided by Acquire Media